Skip to content

Depression research published in 2021

Page 4 of 13: studies 61 to 80 of 247, newest first. Back to the depression overview

Studies

Psilocybin: Next to treat depression, OCD and nicotine addiction

Alcoholism & Drug Abuse Weekly September 24, 2021 Alison Knopf

First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.

Effects of an eight-week, online mindfulness program on anxiety and depression in university students during COVID-19: A randomized controlled trial

Psychiatry Research September 23, 2021 Otto Simonsson, Olivier Bazin, S. Fisher et al.

The COVID-19 pandemic has had adverse mental health effects for many groups in British society, especially young adults and university students. The present study reports secondary outcomes (i.e., symptoms of anxiety and depression) from a randomized waitlist controlled trial, with a one-month post-intervention follow-up, on the effects of a guided, eight-week mindfulness program delivered...

NOVEL MANAGEMENT OF DEPRESSION USING KETAMINE IN THE INTENSIVE CARE UNIT

medRxiv Preprint Server September 23, 2021 Nirmaljot Kaur, Siva Naga S. Yarrarapu, Abhishek R. Giri et al. preprint

Background Ketamine, a dissociative anesthetic, induces remission of depression by antagonizing glutaminergic NMDA receptors. Ketamine has been used previously in outpatient setting for treatment-resistant depression, but we showcase its utility in depression management at the Intensive Care Unit (ICU).

DOI: 10.1101/2021.09.23.21262316 (opens in new tab) Full text (opens in new tab) Ketamine depression treatment Intensive care psychiatry Rapid antidepressant effect Novel therapies

Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies

Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...

DOI: 10.1016/j.jadr.2021.100240 (opens in new tab) Full text (opens in new tab) Psilocybin Depression economics Bipolar disorder Psychotherapist +3

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

Mantra meditation as adjunctive therapy in major depression: A randomized controlled trial

Journal of Affective Disorders Reports September 17, 2021 Holger C Bringmann, Aline Sulz, Philipp Ritter et al.

Objective: To investigate the efficacy of add-on mantra meditation compared to progressive muscle relaxation in major depression. Methods: This study was a two-arm, single-site, raterblinded, randomized controlled trial involving 123 inpatients at a psychiatric hospital diagnosed with major depression according to DSM-IV criteria (January 2017 to June 2020). The treatment group practiced mantra...

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine

Journal of Neuroinflammation September 15, 2021 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al. 61 citations

Treatment-resistant depression (TRD) and pain frequently coexist clinically. Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain. Our aims were to determine the difference in ketamine’s antidepressant effects in TRD patients with or without pain and then to...

Is MDD the right target for early-stage psychedelic-assisted therapy trials?

Journal of Psychedelic Studies September 15, 2021 Benjamin R. Lewis, Kevin Byrne 1 citation

Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major Depressive Disorder (MDD) should raise concerns for this illness category as a target of early psychedelic research given a goal of FDA approval. There are three reasons why MDD is the wrong...

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis

Journal of Psychopharmacology September 14, 2021 Robert F. Leger, Ellen M. Unterwald 54 citations

Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and enduring positive effect on mood. However, marked heterogeneity between methodological designs in this emerging field remains a significant concern. Aims: To determine how differences in the type of psychedelic agent used and...

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Journal of Neurochemistry September 14, 2021 Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr et al. 78 citations

Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long‐term after only a single treatment. Indeed, the Food and Drug...

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.

Cochrane Database of Systematic Reviews September 12, 2021 Rebecca L. Dean, Claudia C. Hurducas, Keith Hawton et al. 97 citations

BACKGROUND Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor...

Mindfulness-Based Approaches for Managing Stress, Anxiety and Depression for Health Students in Tertiary Education: a Scoping Review

Mindfulness September 11, 2021 Dave Parsons, P. Gardner, Sharon Parry et al.

High rates of depression, anxiety and stress are reported in tertiary health students. Mindfulness-based programs have been included in the training of health students to help them manage depression, anxiety and stress; however, to date, there has been no review of best practice implementation of mindfulness for health students. The aim of this review was to evaluate the outcomes of...

A mindfulness meditation mobile app improves depression and anxiety in adults with sleep disturbance: Analysis from a randomized controlled trial

General Hospital Psychiatry September 11, 2021 Jennifer Huberty, Megan E. Puzia, Jeni Green et al. 76 citations

OBJECTIVE: The objective of this study was to 1) determine the effects of a meditation app on depression and anxiety in adults with sleep disturbance, and 2) explore the potential mediating effects of fatigue, daytime sleepiness, and pre-sleep arousal on the relationship between use of the meditation app and changes in depression and anxiety. METHODS: Participants were 239 adults with elevated...

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research

Journal of Holistic Nursing September 6, 2021 Rebecca H Lehto, Megan Miller, Jessica Sender 16 citations

Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer. Psilocybin is a naturally occurring...

The Relationship Between Mindfulness, Depression, Anxiety, and Quality of Life in Individuals With Schizophrenia Spectrum Disorders

Frontiers in Psychology September 3, 2021 Niklas Bergmann, Eric Hahn, Inge Hahne et al.

Background: Schizophrenia spectrum disorders (SSD) are frequently accompanied by comorbid depressive and anxiety symptoms, as well as impaired quality of life (QoL). A growing body of evidence has demonstrated the relevance of mindfulness for SSD in recent years. The study examined the association between mindfulness, depression, anxiety, and QoL.Materials and Methods: A total of 83...

miR-98-5p plays a critical role in depression and antidepressant effect of ketamine

Translational Psychiatry September 3, 2021 Chao Huang, Yuanyuan Wang, Zifeng Wu et al. 29 citations

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...

KETAMINE THERAPY COMBINED WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) FOR MAJOR DEPRESSIVE DISORDER AT A SUBURBAN TERTIARY CLINIC

Brain Stimulation September 1, 2021 M. Davila, A. Hess, Ananya Louviere et al.

Background: Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique approved for the treatment of major https://doi.org/10.1016/j.brs.2021.07.023 depressive disorder (MDD) impacting orbital frontal cortex functioning. We have previously identified significant changes in ratings for several standard metrics for depression, anxiety, pain and ADHD after 6 weeks of...

Anxiety, depression-like behaviors and biochemistry disorders induced by cannabis extract in female mice

Saudi Journal of Biological Sciences September 1, 2021 Atheer M. Mohammed, Ibrahim A. Khardali, Magbool E. Oraiby et al. 7 citations

Cannabis is an annual herbaceous plant sometimes grown for decoration and used as bird food that looks like flax. The study wanted to determine if a Cannabis extract may have an effect on how anxious and depressed the female mice behaved. forty healthy female mice were divided into four groups. Tap water was administered to the first group (control). Ethanol was administered to second group...

Can a little bit of mindfulness do you good? A systematic review and meta-analyses of unguided mindfulness-based self-help interventions.

Clinical Psychology Review August 30, 2021 Heather B Taylor, Clara Strauss, Kate Cavanagh

Over the last decade there has been an explosion of interest in mindfulness-based self-help (MBSH) interventions. While widely available and extensively promoted, there is little consensus on their impact in public health or healthcare contexts. We present a systematic review and meta-analyses of 83 randomized controlled trials, comparing unguided MBSH to control conditions on outcomes of...